118 related articles for article (PubMed ID: 35149615)
1. Unusual Ovarian Tumors With Endometrioid Proliferations Co-Expressing Estrogen Receptor and CDX-2 Arising in Cystadenofibromatous Background: Report of 3 Cases.
McMullen-Tabry ER; Sciallis AP; Udager AM; Skala SL
Int J Gynecol Pathol; 2023 Jan; 42(1):93-100. PubMed ID: 35149615
[TBL] [Abstract][Full Text] [Related]
2. Endometrial, Ovarian, and Peritoneal Involvement by Endometrioid Carcinoma, Yolk Sac Tumor, and Endometriosis: Molecular Evidence for a Shared Precursor.
Halling GC; Udager AM; Skala SL
Int J Gynecol Pathol; 2023 May; 42(3):247-253. PubMed ID: 35639393
[TBL] [Abstract][Full Text] [Related]
3. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
[TBL] [Abstract][Full Text] [Related]
4. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
5. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
6. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
[TBL] [Abstract][Full Text] [Related]
7. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
9. A mouse model for endometrioid ovarian cancer arising from the distal oviduct.
van der Horst PH; van der Zee M; Heijmans-Antonissen C; Jia Y; DeMayo FJ; Lydon JP; van Deurzen CH; Ewing PC; Burger CW; Blok LJ
Int J Cancer; 2014 Sep; 135(5):1028-37. PubMed ID: 24474556
[TBL] [Abstract][Full Text] [Related]
10. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
[TBL] [Abstract][Full Text] [Related]
11. CTNNB1 p.L31P mutation in an ovarian endometrioid carcinoma with synchronous uterine endometrioid carcinoma.
Pecorella I; Coppa A; Nicolussi A; Manganaro L; Fiorentin F; Palaia I; Muzii L
Pathol Res Pract; 2020 Dec; 216(12):153260. PubMed ID: 33120166
[TBL] [Abstract][Full Text] [Related]
12. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
[TBL] [Abstract][Full Text] [Related]
13. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
McCluggage WG; Young RH
Semin Diagn Pathol; 2005 Feb; 22(1):3-32. PubMed ID: 16512597
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas.
Palacios J; Gamallo C
Cancer Res; 1998 Apr; 58(7):1344-7. PubMed ID: 9537226
[TBL] [Abstract][Full Text] [Related]
16. An integrated molecular profile of endometrioid ovarian cancer.
Pierson WE; Peters PN; Chang MT; Chen LM; Quigley DA; Ashworth A; Chapman JS
Gynecol Oncol; 2020 Apr; 157(1):55-61. PubMed ID: 32139151
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
[TBL] [Abstract][Full Text] [Related]
18. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
Costigan DC; Dong F; Nucci MR; Howitt BE
Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and immunohistochemical characterization of papillary proliferation of the endometrium: A single institutional experience.
Park CK; Yoon G; Cho YA; Kim HS
Oncotarget; 2016 Jun; 7(26):39197-39206. PubMed ID: 27322430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]